Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DNLI

Denali Therapeutics Inc

Feb 13 • 11:31AM ET

19.93

+0.75 3.91 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN ALNY UTHR IONS MRNA SRPT NBIX VRTX PTCT

| Held by: VTI XBI IWM VB VBK VXF IWN IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.91	Insider Own	10.40%	Shs Outstand	146.63M	Perf Week	-5.46%
Market Cap	3.11B	Forward P/E	-	EPS next Y	-2.87	Insider Trans	-0.36%	Shs Float	139.92M	Perf Month	9.09%
Enterprise Value	2.31B	PEG	-	EPS next Q	-0.74	Inst Own	93.51%	Short Float	9.69%	Perf Quarter	13.76%
Income	-498.74M	P/S	-	EPS this Y	-15.13%	Inst Trans	4.01%	Short Ratio	8.31	Perf Half Y	37.83%
Sales	0.00M	P/B	3.16	EPS next Y	3.15%	ROA	-39.75%	Short Interest	13.56M	Perf YTD	20.71%
Book/sh	6.32	P/C	3.67	EPS next 5Y	-0.12%	ROE	-44.44%	52W High	23.77 -16.15%	Perf Year	-6.48%
Cash/sh	5.43	P/FCF	-	EPS past 3/5Y	-2.44% -4.46%	ROIC	-51.87%	52W Low	10.57 88.55%	Perf 3Y	-33.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.39% 6.81%	Perf 5Y	-70.48%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.30%	Oper. Margin	-	ATR (14)	1.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.79	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	51.10	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	9.79	EPS Q/Q	-16.35%	SMA20	-2.23%	Beta	1.04	Target Price	32.86
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	6.56%	Rel Volume	0.38	Prev Close	19.18
Employees	422	LT Debt/Eq	0.04	Earnings	Nov 06 AMC	SMA200	25.19%	Avg Volume	1.63M	Price	19.93
IPO	Dec 08, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.03% -100.00%	Trades		Volume	213,820	Change	3.91%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Resumed	UBS	Buy	$25
Apr-10-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-07-25	Resumed	Morgan Stanley	Overweight	$41 → $33
Feb-11-25	Initiated	Deutsche Bank	Buy	$31
Jan-07-25	Initiated	Robert W. Baird	Outperform	$31
Jan-03-25	Initiated	William Blair	Outperform
Dec-16-24	Upgrade	Stifel	Hold → Buy	$37
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-07-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-13-23	Initiated	Citigroup	Buy	$32
Nov-20-23	Resumed	JP Morgan	Overweight	$28
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$85 → $35
Sep-06-23	Initiated	B. Riley Securities	Buy	$38
Jan-30-23	Initiated	SVB Securities	Outperform	$50
Dec-05-22	Initiated	Cowen	Outperform
Nov-02-22	Upgrade	BTIG Research	Neutral → Buy	$38
Nov-02-22	Initiated	BofA Securities	Buy	$40
Jun-23-22	Initiated	Berenberg	Buy	$39
Dec-10-21	Resumed	Raymond James	Mkt Perform
Sep-21-21	Initiated	Oppenheimer	Outperform	$85

Show Previous Ratings

Feb-10-26 08:51AM	FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment (Benzinga)
Feb-05-26 05:30PM	Denali Therapeutics Showcases ETV Data at WORLD: TIVI PDUFA Near, DNL126 Hits 80% CSF Drop (MarketBeat) -5.92% +5.29%
02:00PM	Denali Therapeutics Presents Enzyme TransportVehicle Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium (GlobeNewswire)
Feb-03-26 10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
Feb-02-26 08:00AM	Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle Programs at the 2026 WORLDSymposium (GlobeNewswire)
04:00PM	Loading…
Jan-29-26 04:00PM	Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium (GlobeNewswire)
Jan-20-26 10:42AM	3 Biotech Stocks That Could Double In 2026 (24/7 Wall St.)
Jan-07-26 01:01PM	Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up (Zacks)
Jan-06-26 08:00AM	Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome (GlobeNewswire) +7.43%
Dec-30-25 08:00AM	The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) (GlobeNewswire)
Dec-29-25 09:13AM	3 Biotech Stocks With Major 2026 Catalysts (Zacks)
Dec-22-25 06:11AM	Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? (Insider Monkey)
Dec-10-25 04:58PM	Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More (Motley Fool) -10.63%
12:14AM	Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-09-25 04:01PM	Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
09:56AM	Loading…
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 07:00AM	Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement (GlobeNewswire) +5.84%
Nov-10-25 08:19PM	H.C. Wainwright Reiterates "Buy" Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results (Insider Monkey) +12.69%
Nov-07-25 01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
Nov-06-25 04:01PM	Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
04:00PM	Denali Therapeutics Announces Board and Executive Leadership Updates (GlobeNewswire)
Oct-14-25 08:23AM	FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months (Zacks)
07:53AM	AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance (BioPharma Dive)
Oct-13-25 04:01PM	Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Sep-10-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? (Zacks)
Aug-12-25 08:18AM	DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 (Zacks) -5.03%
Aug-11-25 04:01PM	Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Aug-07-25 05:15AM	Clinical trial supply chains in the US navigate pharma tariffs (Clinical Trials Arena)
Aug-05-25 09:32AM	Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? (Zacks)
11:58AM	Loading…
Jul-31-25 11:58AM	Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy (Insider Monkey)
Jul-30-25 08:55AM	Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue? (Zacks)
Jul-17-25 08:15AM	Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Companys Board of Directors (GlobeNewswire)
Jul-16-25 09:38AM	BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target (Insider Monkey)
Jul-08-25 09:59AM	DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review (Zacks)
Jul-07-25 08:00AM	Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) (GlobeNewswire)
Jun-25-25 03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
Jun-05-25 11:30AM	Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? (Zacks)
May-07-25 01:10PM	Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus (Zacks)
May-06-25 04:01PM	Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome (GlobeNewswire) -12.63%
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
May-02-25 01:20PM	Viatris Q1 Earnings Release: What's in Store for the Stock? (Zacks)
Apr-29-25 06:42AM	Can Amgen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-03-25 09:32AM	DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up (Zacks) -6.91%
Apr-02-25 08:00AM	Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program (GlobeNewswire) +11.80%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 02:16PM	Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (SeekingAlpha)
08:57AM	Why You Shouldn't Bet Against Denali (DNLI) Stock (Zacks)
Mar-04-25 08:00AM	Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer (TipRanks)
Mar-03-25 12:49PM	Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos Investments in 2025? (Insider Monkey) -8.21%
Feb-27-25 04:01PM	Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) -10.97%
Feb-06-25 11:42AM	Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa (GlobeNewswire)
Jan-30-25 08:00AM	Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium (GlobeNewswire)
Jan-17-25 11:18AM	Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-13-25 08:00AM	Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases (GlobeNewswire)
Jan-08-25 08:00AM	Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) (GlobeNewswire)
07:25AM	Denali Therapeutics price target lowered to $32 from $35 at BTIG (TipRanks)
Jan-07-25 04:33PM	These Stocks Moved the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com) +6.86%
04:08PM	Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment (Investor's Business Daily)
02:16PM	These Stocks Are Moving the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More (Barrons.com)
12:48PM	Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected (Benzinga)
10:13AM	Denali Therapeutics Phase II/III trial of ALS therapy fails to meet primary endpoint (Clinical Trials Arena)
10:13AM	Denali Therapeutics ALS therapy fails to meet primary endpoint in Phase II/III trial (Clinical Trials Arena)
09:33AM	Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. (Investor's Business Daily)
04:41AM	ALS drugs from Denali, Calico come up short, marking setback for Healey trial (BioPharma Dive)
Jan-06-25 04:30PM	Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire) -6.77%
Jan-03-25 01:08PM	Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic (Benzinga)
Dec-17-24 06:25AM	Denali Therapeutics upgraded to Buy from Hold at Stifel (TipRanks)
Dec-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? (Zacks) +6.73%
Dec-05-24 08:00AM	Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease (GlobeNewswire)
Nov-06-24 04:01PM	Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.87%
Oct-29-24 10:01AM	Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-13-24 04:56PM	Denali Therapeutics Inc. (DNLI): Jeff Bezos Is Buying This Stock Now (Insider Monkey)
Sep-16-24 11:22AM	Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? (Zacks)
Sep-04-24 08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 08:00AM	Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) (GlobeNewswire)
Aug-19-24 10:13AM	Genetic testing in Parkinsons disease patients: a standard of care imperative? (Medical Device Network)
Aug-14-24 02:00PM	Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration (GlobeNewswire)
Aug-06-24 09:55AM	Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade (Zacks)
Aug-01-24 06:45AM	Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jul-23-24 06:13AM	Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar? (Zacks)
Jul-16-24 03:19PM	Denali Therapeutics Stock Gets Technical Rating Upgrade (Investor's Business Daily)
Jul-08-24 07:09PM	3 Longevity Stocks to Buy for Anti-Aging Breakthroughs (InvestorPlace)
Jun-28-24 08:37AM	Denali (DNLI) Outperforms Industry in 3 Months: Here's Why (Zacks)
Jun-24-24 09:07AM	Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last? (Zacks)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
Jun-06-24 11:31AM	Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report? (Zacks)
Jun-04-24 01:17PM	Denali's (DNLI) Candidate Selected for FDA's START Pilot Program (Zacks)
Jun-03-24 08:00AM	Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies (GlobeNewswire) +9.81%
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
May-08-24 11:17AM	Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating (MT Newswires) +12.17%
09:16AM	Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating (MT Newswires)
08:20AM	Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus (Zacks)
May-07-24 10:56PM	DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:56PM	Denali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic Shifts (GuruFocus.com)
04:01PM	Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-01-24 08:00AM	Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial (GlobeNewswire)
Apr-09-24 08:46AM	Why Denali Therapeutics (DNLI) Stock Might be a Great Pick (Zacks)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Mar-28-24 11:30AM	Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? (Zacks)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CAROLE HO	Former Affiliate	Feb 05 '26	Proposed Sale	20.29	39,490	801,394		Feb 05 04:14 PM
CAROLE HO	Former Affiliate	Feb 04 '26	Proposed Sale	21.18	150,000	3,176,970		Feb 04 04:16 PM
CAROLE HO	Former Affiliate	Feb 03 '26	Proposed Sale	22.16	150,000	3,324,060		Feb 03 04:47 PM
Watts Ryan J.	President and CEO	Jan 06 '26	Sale	16.50	35,198	580,767	296,833	Jan 08 04:20 PM
Schuth Alexander O.	COFO and Secretary	Jan 06 '26	Sale	16.50	17,218	284,097	282,828	Jan 08 04:19 PM
Ho Carole	Consultant	Jan 06 '26	Proposed Sale	16.50	17,218	284,097		Jan 06 08:28 PM
Schuth Alexander O.	Officer	Jan 06 '26	Proposed Sale	16.50	17,218	284,097		Jan 06 08:25 PM
Watts Ryan J.	Director	Jan 06 '26	Proposed Sale	16.50	35,198	580,767		Jan 06 08:24 PM
CAROLE HO	Officer	Dec 04 '25	Proposed Sale	19.00	1,882	35,758		Dec 04 04:41 PM
Schuth Alexander O.	COFO and Secretary	Aug 12 '25	Sale	13.58	2,937	39,884	242,346	Aug 14 08:33 PM
Ho Carole	Chief Medical Officer	Aug 12 '25	Sale	13.58	2,937	39,884	217,391	Aug 14 08:33 PM
Ho Carole	Chief Medical Officer	Aug 13 '25	Sale	14.64	806	11,800	216,585	Aug 14 08:33 PM
CAROLE HO	Officer	Aug 13 '25	Proposed Sale	13.22	806	10,655		Aug 13 04:45 PM
Schuth Alexander O.	Officer	Aug 12 '25	Proposed Sale	13.58	2,937	39,876		Aug 12 08:46 PM
Ho Carole	Officer	Aug 12 '25	Proposed Sale	13.58	2,937	39,876		Aug 12 08:44 PM
Ho Carole	Chief Medical Officer	Aug 05 '25	Option Exercise	0.68	44,655	30,365	220,328	Aug 07 05:34 PM
Watts Ryan J.	President and CEO	Jul 09 '25	Option Exercise	1.05	495,282	520,792	748,353	Jul 11 05:13 PM
Watts Ryan J.	President and CEO	Jul 09 '25	Sale	15.00	495,282	7,429,230	253,071	Jul 11 05:13 PM
Watts Ryan J.	Officer	Jul 09 '25	Proposed Sale	14.33	495,282	7,097,391		Jul 09 04:13 PM

Open in Screener

AGIO

Agios Pharmaceuticals Inc

Feb 13 • 11:31AM ET

28.77

+0.70 2.51 %

Healthcare • Biotechnology • USA • NASD

AGIO Agios Pharmaceuticals Inc daily Stock Chart

Peers: AMGN REGN VRTX GILD ALNY SRPT NBIX BLUE FOLD NVAX

| Held by: XBI VTI IWM VB VBK VXF IWN IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-6.96	Insider Own	5.84%	Shs Outstand	58.28M	Perf Week	8.46%
Market Cap	1.68B	Forward P/E	-	EPS next Y	-5.19	Insider Trans	-1.51%	Shs Float	54.91M	Perf Month	0.16%
Enterprise Value	769.64M	PEG	-	EPS next Q	-1.77	Inst Own	102.10%	Short Float	12.25%	Perf Quarter	-34.05%
Income	-401.26M	P/S	37.46	EPS this Y	8.70%	Inst Trans	-4.44%	Short Ratio	4.01	Perf Half Y	-21.55%
Sales	44.79M	P/B	1.31	EPS next Y	20.09%	ROA	-25.26%	Short Interest	6.73M	Perf YTD	5.71%
Book/sh	22.04	P/C	1.76	EPS next 5Y	18.67%	ROE	-27.57%	52W High	46.00 -37.45%	Perf Year	-13.59%
Cash/sh	16.34	P/FCF	-	EPS past 3/5Y	- -	ROIC	-30.61%	52W Low	22.24 29.38%	Perf 3Y	-0.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -20.91%	Gross Margin	75.43%	Volatility	4.52% 4.44%	Perf 5Y	-48.51%
Dividend TTM	-	EV/Sales	17.18	EPS Y/Y TTM	-158.98%	Oper. Margin	-1061.80%	ATR (14)	1.23	Perf 10Y	-23.80%
Dividend Ex-Date	-	Quick Ratio	13.39	Sales Y/Y TTM	36.26%	Profit Margin	-895.86%	RSI (14)	56.79	Recom	1.60
Dividend Gr. 3/5Y	- -	Current Ratio	13.82	EPS Q/Q	-110.97%	SMA20	3.77%	Beta	0.90	Target Price	38.12
Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	43.69%	SMA50	5.02%	Rel Volume	0.24	Prev Close	28.07
Employees	488	LT Debt/Eq	0.02	Earnings	Feb 12 BMO	SMA200	-15.58%	Avg Volume	1.68M	Price	28.77
IPO	Jul 24, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.80% 65.14%	Trades		Volume	138,569	Change	2.51%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Truist	Buy
Nov-20-25	Upgrade	Leerink Partners	Market Perform → Outperform	$34
Nov-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$28
Feb-24-25	Initiated	H.C. Wainwright	Buy	$58
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform	$51
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform	$60 → $56
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight	$41
Nov-17-22	Upgrade	Goldman	Sell → Neutral	$17 → $32
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$33
Dec-03-21	Initiated	BofA Securities	Buy	$54
Jul-30-21	Downgrade	Goldman	Neutral → Sell	$58 → $39
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy	$88
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$50
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral	$64 → $54
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight	$46
Mar-04-20	Initiated	Barclays	Equal Weight	$50

Show Previous Ratings

Today 10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
Feb-12-26 02:02PM	Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:31PM	Agios Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
07:40AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
06:40AM	Agios Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Loading…
06:30AM	Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-05-26 10:00AM	Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-04-26 08:41AM	Williams to Report Q4 Earnings: What Surprise Awaits Investors? (Zacks)
Jan-26-26 07:00AM	Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET (GlobeNewswire)
Jan-19-26 05:19PM	Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory (Insider Monkey)
Jan-14-26 01:16PM	Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline (MarketBeat)
Jan-13-26 07:27AM	Agios Pharmaceuticals outlines 2026 strategic priorities (TipRanks)
Jan-12-26 07:00AM	Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth (GlobeNewswire)
Jan-05-26 07:00AM	Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (GlobeNewswire)
Dec-26-25 08:42AM	Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains? (Zacks)
10:39AM	Loading…
Dec-25-25 10:39AM	Agios (AGIO) Gets 18.6% Boost from Aqvesme OK (Insider Monkey)
06:05AM	Agios Pharmaceuticals price target raised to $34 from $32 at BofA (TipRanks)
Dec-24-25 12:23PM	Here's Why Shares in Agios Pharmaceuticals Popped Today (Motley Fool) +18.63%
11:05AM	AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label (Zacks)
Dec-23-25 07:45PM	U.S. FDA Approves Agios' AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia (GlobeNewswire)
Dec-09-25 10:24AM	Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date (Zacks)
Dec-08-25 07:00AM	Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia (GlobeNewswire)
Nov-25-25 08:39AM	Agios Pharmaceuticals (AGIO) Upgraded After Mixed Sickle Cell Data and Pending Thalassemia Catalyst (Insider Monkey) +7.30%
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks) +9.98%
Nov-19-25 04:22PM	Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged (Investor's Business Daily) -50.89%
01:33PM	Why Shares in Agios Pharmaceuticals Got Crushed Today (Motley Fool)
11:30AM	A Sickle Cell Trial Delivers Mixed Results. Agios Stock Falls by 48%. (Barrons.com)
07:00AM	Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease (GlobeNewswire)
Nov-03-25 09:01AM	Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition (GlobeNewswire) -7.19%
Oct-31-25 01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
04:19PM	Loading…
Oct-30-25 04:19PM	Agios Pharmaceuticals Inc (AGIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
07:40AM	Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:36AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-17-25 08:00AM	Agios' PYRUKYND (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia (GlobeNewswire)
Oct-16-25 07:00AM	Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET (GlobeNewswire)
Sep-05-25 10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Sep-04-25 07:00AM	Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND (mitapivat) in Thalassemia (GlobeNewswire) -11.03%
Sep-03-25 11:30AM	Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report? (Zacks)
Aug-29-25 05:00AM	Agios Pharmaceuticals, Inc. (AGIO) Advances Pipeline With Tebapivat, AG-236 in Rare Blood Disorders (Insider Monkey)
Aug-04-25 04:01PM	Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia (GlobeNewswire)
09:46AM	Agios shares drop after report notes deaths of Pyrukynd patients (Investing.com)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
06:36AM	Agios Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-14-25 07:00AM	Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET (GlobeNewswire)
Jul-08-25 07:00AM	Agios Appoints Dr. Jay Backstrom to Board of Directors (GlobeNewswire)
Jun-17-25 01:37PM	Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat's Market Potential (Insider Monkey)
Jun-15-25 05:43AM	H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT (Insider Monkey)
Jun-09-25 08:40AM	Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders (Business Wire)
Jun-05-25 11:31AM	Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-04-25 11:30AM	Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
May-28-25 07:00AM	Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 (GlobeNewswire)
May-14-25 10:00AM	Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress (GlobeNewswire)
May-09-25 07:00AM	Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 (GlobeNewswire)
May-02-25 07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
07:00AM	Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 (GlobeNewswire)
03:02AM	Agios Pharmaceuticals Inc (AGIO) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
May-01-25 12:06PM	Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:50AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:47AM	Agios Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-24-25 10:02AM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-17-25 07:00AM	Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 (GlobeNewswire)
Apr-08-25 06:24AM	New Strong Sell Stocks for April 8th (Zacks) -5.29%
Apr-03-25 03:54AM	New Strong Sell Stocks for April 3rd (Zacks)
Mar-27-25 05:35AM	Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? (Zacks)
Mar-26-25 09:39PM	Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-05-25 05:52PM	Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer (GlobeNewswire)
Mar-04-25 07:00AM	Agios to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-01-25 09:20AM	Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
Feb-20-25 07:00AM	Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 (GlobeNewswire)
Feb-15-25 10:05AM	Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank (TipRanks)
Feb-14-25 02:09AM	Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Feb-13-25 12:45PM	Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years (Benzinga)
07:45AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:31AM	Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint (GlobeNewswire)
Feb-12-25 10:25AM	Agios Pharmaceuticals price target lowered to $54 from $55 at BofA (TipRanks)
08:05AM	Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-06-25 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 (GlobeNewswire)
Jan-13-25 04:29PM	Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential (Insider Monkey)
07:00AM	Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio (GlobeNewswire)
Jan-08-25 07:00AM	FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia (GlobeNewswire)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal)
07:00AM	Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 (GlobeNewswire)
Dec-18-24 07:00AM	European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease (GlobeNewswire) -7.01%
Dec-10-24 09:39AM	Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank (TipRanks) -5.39%
Dec-09-24 04:21PM	Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug (Investor's Business Daily) -21.09%
Dec-08-24 12:40PM	Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat (GlobeNewswire)
Dec-05-24 08:42AM	Are Options Traders Betting on a Big Move in Agios (AGIO) Stock? (Zacks)
Nov-26-24 09:40AM	Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-05-24 09:05AM	Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-01-24 03:03AM	Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Oct-31-24 07:45AM	Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates (Zacks)
06:42AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-23-24 07:00AM	Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease (GlobeNewswire)
Oct-17-24 07:00AM	Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 (GlobeNewswire)
Sep-27-24 10:34AM	Do Options Traders Know Something About Agios (AGIO) Stock We Don't? (Zacks) -5.08%

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Milanova Tsveta	Chief Commercial Officer	Jan 05 '26	Option Exercise	0.00	8,475	0	37,665	Jan 07 04:23 PM
Milanova Tsveta	Chief Commercial Officer	Jan 05 '26	Sale	27.02	2,872	77,601	34,793	Jan 07 04:23 PM
Milanova Tsveta	Officer	Jan 05 '26	Proposed Sale	27.22	2,872	78,176		Jan 05 04:05 PM
Burns James William	Chief Legal Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	34,650	Jan 02 08:18 PM
Burns James William	Chief Legal Officer	Dec 30 '25	Sale	27.09	2,932	79,428	31,718	Jan 02 08:18 PM
Goff Brian	Chief Executive Officer	Dec 30 '25	Option Exercise	0.00	38,278	0	149,333	Jan 02 08:16 PM
Goff Brian	Chief Executive Officer	Dec 30 '25	Sale	27.09	18,703	506,664	136,583	Jan 02 08:16 PM
Gheuens Sarah	Chief Medical Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	67,727	Jan 02 08:15 PM
Gheuens Sarah	Chief Medical Officer	Dec 30 '25	Sale	27.09	2,932	79,428	64,795	Jan 02 08:15 PM
Milanova Tsveta	Chief Commercial Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	32,122	Jan 02 08:15 PM
Milanova Tsveta	Chief Commercial Officer	Dec 30 '25	Sale	27.09	2,932	79,428	29,190	Jan 02 08:15 PM
Jones Cecilia	Chief Financial Officer	Dec 30 '25	Option Exercise	0.00	6,000	0	40,326	Jan 02 08:14 PM
Jones Cecilia	Chief Financial Officer	Dec 30 '25	Sale	27.09	2,932	79,428	37,394	Jan 02 08:14 PM
Goff Brian	Officer	Dec 30 '25	Proposed Sale	27.16	18,703	507,973		Dec 30 04:20 PM
Gheuens Sarah	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:18 PM
Jones Cecilia	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:16 PM
Milanova Tsveta	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:13 PM
Burns James William	Officer	Dec 30 '25	Proposed Sale	27.16	2,932	79,633		Dec 30 04:11 PM
Scadden David	Director	Nov 12 '25	Option Exercise	18.09	200	3,618	17,803	Nov 14 04:04 PM
Scadden David	Director	Nov 12 '25	Sale	43.84	200	8,768	17,603	Nov 14 04:04 PM
Gheuens Sarah	Chief Medical Officer	Nov 11 '25	Option Exercise	25.01	2,454	61,375	64,181	Nov 13 04:08 PM
Gheuens Sarah	Chief Medical Officer	Nov 11 '25	Sale	43.78	2,454	107,436	61,727	Nov 13 04:08 PM
SARAH GHEUENS	Officer	Nov 11 '25	Proposed Sale	43.78	2,454	107,441		Nov 12 10:35 AM
Gheuens Sarah	Chief Medical Officer	Oct 30 '25	Option Exercise	25.01	200	5,002	61,927	Nov 03 04:10 PM
Gheuens Sarah	Chief Medical Officer	Oct 30 '25	Sale	43.81	200	8,762	61,727	Nov 03 04:10 PM
SARAH GHEUENS	Officer	Oct 30 '25	Proposed Sale	43.81	200	8,762		Oct 30 05:02 PM
Gheuens Sarah	Chief Medical Officer	Oct 27 '25	Option Exercise	25.01	3,302	82,583	65,029	Oct 29 04:02 PM
Gheuens Sarah	Chief Medical Officer	Oct 27 '25	Sale	43.92	3,302	145,024	61,727	Oct 29 04:02 PM
SARAH GHEUENS	Officer	Oct 27 '25	Proposed Sale	43.92	3,302	145,028		Oct 27 04:32 PM
Scadden David	Director	Oct 08 '25	Option Exercise	18.09	200	3,618	17,803	Oct 10 04:18 PM
Scadden David	Director	Oct 08 '25	Sale	41.00	200	8,200	17,603	Oct 10 04:18 PM
DAVID SCADDEN	Director	Oct 08 '25	Proposed Sale	41.00	200	8,200		Oct 08 04:01 PM
Scadden David	Director	Sep 30 '25	Option Exercise	18.09	200	3,618	17,803	Oct 02 04:03 PM
Scadden David	Director	Sep 30 '25	Sale	40.00	200	8,000	17,603	Oct 02 04:03 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '25	Option Exercise	0.00	7,472	0	37,521	Sep 30 05:56 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '25	Sale	36.77	3,651	134,247	33,870	Sep 30 05:56 PM
DAVID SCADDEN	Director	Sep 30 '25	Proposed Sale	40.00	200	8,000		Sep 30 04:48 PM
Jones Cecilia	Officer	Sep 26 '25	Proposed Sale	36.77	3,651	134,247		Sep 26 04:15 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Sep 05 '25	Sale	36.87	8,546	315,091	868	Sep 09 04:26 PM
Scadden David	Director	Aug 27 '25	Option Exercise	18.09	200	3,618	17,803	Aug 29 04:09 PM
Scadden David	Director	Aug 27 '25	Sale	40.00	200	8,000	17,603	Aug 29 04:09 PM
DAVID T. SCADDEN	Director	Aug 27 '25	Proposed Sale	40.00	200	8,000		Aug 27 04:13 PM
Ballal Rahul D.	Director	Aug 11 '25	Option Exercise	0.00	2,302	0	12,414	Aug 13 04:55 PM
Smith Cynthia	Director	Aug 11 '25	Option Exercise	0.00	2,302	0	12,414	Aug 13 04:55 PM
Goff Brian	Chief Executive Officer	Aug 08 '25	Option Exercise	0.00	22,691	0	134,613	Aug 12 04:24 PM
Goff Brian	Chief Executive Officer	Aug 08 '25	Sale	36.67	11,085	406,487	123,528	Aug 12 04:24 PM
Goff Brian	Officer	Aug 08 '25	Proposed Sale	37.06	11,085	410,810		Aug 08 06:53 PM
Scadden David	Director	Jul 10 '25	Option Exercise	18.09	1,400	25,326	19,003	Jul 15 04:05 PM
Scadden David	Director	Jul 10 '25	Sale	40.00	1,400	56,000	17,603	Jul 15 04:05 PM
Gheuens Sarah	Chief Medical Officer	Jul 09 '25	Option Exercise	25.01	11,914	297,969	73,185	Jul 11 04:59 PM
Gheuens Sarah	Chief Medical Officer	Jul 09 '25	Sale	37.99	11,914	452,601	61,271	Jul 11 04:59 PM
DAVID SCADDEN	Director	Jul 10 '25	Proposed Sale	40.00	1,400	56,000		Jul 10 05:14 PM
SARAH GHEUENS	Officer	Jul 09 '25	Proposed Sale	37.99	11,914	452,632		Jul 09 04:59 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '25	Option Exercise	0.00	8,374	0	65,362	Jul 03 04:01 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '25	Sale	34.17	4,091	139,789	61,271	Jul 03 04:01 PM
Gheuens Sarah	Officer	Jul 01 '25	Proposed Sale	34.37	4,091	140,608		Jul 01 04:03 PM
Burns James William	Chief Legal Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	31,449	Jun 26 05:26 PM
Burns James William	Chief Legal Officer	Jun 24 '25	Sale	33.54	2,799	93,878	28,650	Jun 26 05:26 PM
Gheuens Sarah	Chief Medical Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	59,897	Jun 26 05:25 PM
Gheuens Sarah	Chief Medical Officer	Jun 24 '25	Sale	33.54	2,909	97,568	56,988	Jun 26 05:25 PM
Jones Cecilia	Chief Financial Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	31,829	Jun 26 05:24 PM
Jones Cecilia	Chief Financial Officer	Jun 24 '25	Sale	33.54	1,780	59,701	30,049	Jun 26 05:24 PM
Milanova Tsveta	Chief Commercial Officer	Jun 24 '25	Option Exercise	0.00	6,000	0	28,892	Jun 26 05:23 PM
Milanova Tsveta	Chief Commercial Officer	Jun 24 '25	Sale	33.54	2,770	92,906	26,122	Jun 26 05:23 PM
Goff Brian	Chief Executive Officer	Jun 24 '25	Option Exercise	0.00	38,277	0	118,151	Jun 26 05:22 PM
Goff Brian	Chief Executive Officer	Jun 24 '25	Sale	33.54	18,700	627,198	105,401	Jun 26 05:22 PM
Goff Brian	Officer	Jun 24 '25	Proposed Sale	34.41	18,507	636,826		Jun 24 04:10 PM
Milanova Tsveta	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:08 PM
Jones Cecilia	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:07 PM
Gheuens Sarah	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:05 PM
Burns James William	Officer	Jun 24 '25	Proposed Sale	34.41	1,761	60,596		Jun 24 04:01 PM
Ballal Rahul D.	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	10,112	Jun 23 04:27 PM
CAPELLO JEFFREY D	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	6,073	Jun 23 04:25 PM
Foster-Cheek Kaye I	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	7,468	Jun 23 04:24 PM
FOUSE JACQUALYN A	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	151,340	Jun 23 04:23 PM
Ho Maykin	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	17,032	Jun 23 04:21 PM
Owen Adams Catherine	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	6,073	Jun 23 04:20 PM
Scadden David	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	17,603	Jun 23 04:18 PM
Smith Cynthia	Director	Jun 20 '25	Option Exercise	0.00	2,120	0	10,112	Jun 23 04:17 PM
CAPELLO JEFFREY D	Director	Jun 13 '25	Option Exercise	0.00	1,977	0	3,953	Jun 17 04:16 PM
Owen Adams Catherine	Director	Jun 13 '25	Option Exercise	0.00	1,977	0	3,953	Jun 17 04:15 PM
FOUSE JACQUALYN A	Director	Apr 08 '25	Option Exercise	0.00	15,933	0	156,717	Apr 10 04:02 PM
FOUSE JACQUALYN A	Director	Apr 10 '25	Sale	25.90	7,497	194,172	149,220	Apr 10 04:02 PM
FOUSE JACQUALYN A	Director	Apr 08 '25	Proposed Sale	25.90	7,497	194,172		Apr 08 05:58 PM
Burns James William	Chief Legal Officer	Mar 01 '25	Option Exercise	0.00	13,500	0	27,130	Mar 04 04:17 PM
Burns James William	Chief Legal Officer	Mar 03 '25	Sale	35.54	4,005	142,338	18,650	Mar 04 04:17 PM
Jones Cecilia	Chief Financial Officer	Mar 01 '25	Option Exercise	0.00	7,667	0	27,510	Mar 04 04:15 PM
Jones Cecilia	Chief Financial Officer	Mar 03 '25	Sale	35.54	2,275	80,854	21,843	Mar 04 04:15 PM
Milanova Tsveta	Chief Commercial Officer	Mar 01 '25	Option Exercise	0.00	5,667	0	24,573	Mar 04 04:12 PM
Milanova Tsveta	Chief Commercial Officer	Mar 03 '25	Sale	35.54	1,681	59,743	22,892	Mar 04 04:12 PM
Goff Brian	Chief Executive Officer	Mar 01 '25	Option Exercise	0.00	26,500	0	101,139	Mar 04 04:10 PM
Goff Brian	Chief Executive Officer	Mar 03 '25	Sale	35.54	12,947	460,136	83,139	Mar 04 04:10 PM
Gheuens Sarah	Chief Medical Officer	Mar 01 '25	Option Exercise	0.00	13,500	0	55,578	Mar 04 04:08 PM
Gheuens Sarah	Chief Medical Officer	Mar 03 '25	Sale	35.54	4,005	142,338	47,098	Mar 04 04:08 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 01 '25	Option Exercise	0.00	5,577	0	10,141	Mar 04 04:06 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 03 '25	Sale	35.54	1,655	58,819	6,038	Mar 04 04:06 PM
Milanova Tsveta	Officer	Mar 03 '25	Proposed Sale	35.54	1,681	59,743		Mar 03 04:50 PM
Jones Cecilia	Officer	Mar 03 '25	Proposed Sale	35.54	2,275	80,854		Mar 03 04:49 PM
Goff Brian	Officer	Mar 03 '25	Proposed Sale	35.54	12,947	460,136		Mar 03 04:46 PM
Gheuens Sarah	Officer	Mar 03 '25	Proposed Sale	35.54	4,005	142,338		Mar 03 04:44 PM

DNLI

Denali Therapeutics Inc

AGIO

Agios Pharmaceuticals Inc

Upgrade your FINVIZ experience